218 related articles for article (PubMed ID: 35433422)
1. The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer.
Asano Y; Yamamoto N; Demura S; Hayashi K; Takeuchi A; Kato S; Miwa S; Igarashi K; Higuchi T; Yonezawa H; Araki Y; Morinaga S; Saito S; Sone T; Kasahara K; Tsuchiya H
Front Oncol; 2022; 12():871675. PubMed ID: 35433422
[TBL] [Abstract][Full Text] [Related]
2. Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors.
Cao Y; Afzal MZ; Shirai K
J Thorac Dis; 2021 Aug; 13(8):4668-4677. PubMed ID: 34527308
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review.
Li HS; Lei SY; Li JL; Xing PY; Hao XZ; Xu F; Xu HY; Wang Y
Front Immunol; 2022; 13():908436. PubMed ID: 36105807
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases.
Asano Y; Yamamoto N; Demura S; Hayashi K; Takeuchi A; Kato S; Miwa S; Igarashi K; Higuchi T; Taniguchi Y; Okuda M; Matsumoto I; Yano S; Tsuchiya H
Lung Cancer; 2024 Jun; 193():107858. PubMed ID: 38901176
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
Front Immunol; 2021; 12():697298. PubMed ID: 34858389
[TBL] [Abstract][Full Text] [Related]
6. Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis.
Asano Y; Yamamoto N; Demura S; Hayashi K; Takeuchi A; Kato S; Miwa S; Igarashi K; Higuchi T; Taniguchi Y; Morinaga S; Sone T; Okuda M; Matsumoto I; Yano S; Tsuchiya H
Cancer Med; 2023 Jun; 12(11):12425-12437. PubMed ID: 37076988
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
8. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
9. Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review.
Tsukamoto S; Mavrogenis AF; Masunaga T; Aiba H; Aso A; Honoki K; Fujii H; Kido A; Tanaka Y; Tanaka Y; Errani C
Eur J Orthop Surg Traumatol; 2024 Jun; ():. PubMed ID: 38836904
[TBL] [Abstract][Full Text] [Related]
10. Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer-a retrospective cohort study.
Wang Q; Fang Y; Li C; Leong TL; Provencio M; Oh IJ; Zhang Z; Su C
Transl Lung Cancer Res; 2023 Feb; 12(2):312-321. PubMed ID: 36895937
[TBL] [Abstract][Full Text] [Related]
11. Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis.
Pantano F; Tramontana F; Iuliani M; Leanza G; Simonetti S; Piccoli A; Paviglianiti A; Cortellini A; Spinelli GP; Longo UG; Strollo R; Vincenzi B; Tonini G; Napoli N; Santini D
J Bone Oncol; 2022 Dec; 37():100459. PubMed ID: 36338920
[TBL] [Abstract][Full Text] [Related]
12. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis of the jaw in a metastatic lung cancer patient with bone metastases undergoing pembrolizumab + denosumab combination therapy: Case report and literature review.
Myoken Y; Fujita Y; Kawamoto K; Toratani S
Oral Oncol; 2020 Dec; 111():104874. PubMed ID: 32605876
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study.
Qiang H; Lei Y; Shen Y; Li J; Zhong H; Zhong R; Zhang X; Chang Q; Lu J; Feng H; Zhu Y; Addeo A; Banna GL; Oh IJ; Qian J; Chu T
Transl Lung Cancer Res; 2022 Jan; 11(1):87-99. PubMed ID: 35242630
[TBL] [Abstract][Full Text] [Related]
15. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.
Miura K; Sano Y; Niho S; Kawasumi K; Mochizuki N; Yoh K; Matsumoto S; Zenke Y; Ikeda T; Nosaki K; Kirita K; Udagawa H; Goto K; Kawasaki T; Hanada K
Thorac Cancer; 2021 Jul; 12(13):1983-1994. PubMed ID: 33990133
[TBL] [Abstract][Full Text] [Related]
16. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
17. Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Qin A; Zhao S; Miah A; Wei L; Patel S; Johns A; Grogan M; Bertino EM; He K; Shields PG; Kalemkerian GP; Gadgeel SM; Ramnath N; Schneider BJ; Hassan KA; Szerlip N; Chopra Z; Journey S; Waninger J; Spakowicz D; Carbone DP; Presley CJ; Otterson GA; Green MD; Owen DH
J Natl Compr Canc Netw; 2021 Apr; 19(8):915-921. PubMed ID: 33878726
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer: Lung Immune Prognostic Index and Immune-Related Toxicity.
Moratiel Pellitero A; Zapata Garcia M; Gascon Ruiz M; Arbones-Mainar JM; Lastra Del Prado R; Isla D
World J Oncol; 2024 Apr; 15(2):223-238. PubMed ID: 38545481
[TBL] [Abstract][Full Text] [Related]
19. An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.
Liede A; Hernandez RK; Wade SW; Bo R; Nussbaum NC; Ahern E; Dougall WC; Smyth MJ
Oncoimmunology; 2018; 7(12):e1480301. PubMed ID: 30524886
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
